NovaBay discontinues studies on NVC-422 for viral conjunctivitis

NovaBay Pharmaceuticals announced in a press release that its phase 2 clinical study for NVC-422 ophthalmic formulation for patients with adenoviral conjunctivitis did not meet primary or secondary endpoints.The endpoints included clearing of bulbar conjunctival injection, eradication of adenovirus from the tear film, spread of infection to the fellow eye, reduction in subepithelial infiltrates and clearing of blurred vision compared to its vehicle at test-of-cure-visit (day 18), according to the press release.